Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | TENX | Common Stock | Options Exercise | +3.07M | +540.62% | 3.64M | Jun 11, 2021 | Direct | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | TENX | Stock Option (right to buy) | Award | $0 | +6.25K | $0.00 | 6.25K | Jun 10, 2021 | Common Stock | 6.25K | $2.00 | Direct | ||
transaction | TENX | Series B Preferred Stock | Options Exercise | -3.07K | -100% | 0 | Jun 11, 2021 | Common Stock | 3.07M | Direct | F1, F2 |
Id | Content |
---|---|
F1 | On June 10, 2021, the shareholders of Tenax Therapeutics, Inc. voted in favor of the conversion of all Series B Preferred Stock to Common Stock. Pursuant to this action, all Series B Preferred Stock owned by the Reporting Person converted automatically to shares of Common Stock on June 11, 2021. |
F2 | As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction. |